Merck & Company (MRK) concentration risks

The company's only disclosed concentration in the 10-K is a product-level exposure to a single pharmaceutical asset. Sales of Keytruda represented 49% of the company's total sales in 2025 — a moderate share by disclosed size with a structural character, reflecting the success of a blockbuster oncology franchise that has grown to define nearly half of the consolidated revenue base. The structural character is appropriate: Keytruda's revenue share reflects years of clinical development, broad label expansion across multiple tumor types, and deep institutional adoption rather than reliance on a single customer or contract. However, the concentration at this level also means that any material disruption to Keytruda's commercial trajectory — whether from patent expiration, biosimilar entry, competitive clinical data, pricing policy changes, or a rare safety signal — would have a proportional impact on the company's total sales with no single offsetting product of comparable scale disclosed in the available claims. There is no disclosed customer, geographic, or supplier concentration layered on top of this product-level tilt in the source claims. On balance, the disclosed profile is narrow: a single moderate-share product concentration that is well understood in the investment community and is primarily driven by competitive and lifecycle dynamics within the immuno-oncology market rather than any idiosyncratic counterparty risk.

For the engine’s reasoning on MRK’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.